3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth. Nam AY, Joo SH, Lee NY, Yoon G, et al. PLoS One 2025;20:e0329706.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nam AY, Joo SH, Lee NY, Yoon G, et al. 3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth. PLoS One 2025;20:e0329706.
PMID: 40920675